CD40LG and neoplasm: Constitutive expression of CD40L by genetic engineering of CAR-Ts (CD40L+ CAR-Ts) can be another strategy for tackling antigen loss-related immune escape of tumor cells by operating through direct and indirect tumoricidal responses (148, 149).